The GLP-1 drugs are revolutionizing the way people eat and spend their money, according to a recent survey. The survey reveals that approximately three million Canadian adults are currently taking GLP-1 drugs like Ozempic or Mounjaro, and many more are interested in doing so. However, cost is a significant barrier for those who want to try these medications. The poll conducted by Leger Healthcare found that over half of the people taking GLP-1 drugs reported a decreased appetite, and 40% said they have fewer food cravings. This is reshaping their spending habits, with around 30% going to restaurants or ordering takeout less frequently. Interestingly, about a third of GLP-1 users are buying more fresh fruits and vegetables, as well as protein-rich foods. The survey also highlights that weight loss is the primary reason people are taking or considering taking GLP-1 medications, followed by diabetes. However, more than half of those interested in taking the medication said having insurance coverage or lower-cost generic options would affect their decision. The rise of GLP-1 drugs has sparked a debate about the body positivity movement. While some argue that these medications are a promising solution for weight loss, others worry that they may trigger the next restaurant crisis. The survey found that 22% of people taking GLP-1 drugs cited heart health as a reason for their use, with men more likely to cite this reason than women. The survey also revealed that a quarter of the respondents taking GLP-1 medications were paying for the drugs out of pocket, which can cost hundreds of dollars a month. The polling industry's professional body, the Canadian Research Insights Council, notes that online surveys cannot be assigned a margin of error due to their non-random sampling method. However, a probability sample of comparable size would yield a margin of error of ±2.5% (19 times out of 20), according to Leger Healthcare.
